Post on 03-Feb-2015
description
transcript
The Cambridge Phenomenon:Solexa, Genome Sequencing
ViaCyte, Stem Cells for Diabetes
John WestCEO, ViaCyte, Inc
Previously CEO, Solexa
1The Cambridge Phenomenon Conference, Oct 5, 2010
Solexa Technology FlowReagents, Instruments, Software, Sequences
2The Cambridge Phenomenon Conference, Oct 5, 2010
Just a few of the UK team...
3The Cambridge Phenomenon Conference, Oct 5, 2010
SG CowenInvestment bankers New York
Solexa, Little ChesterfordEssex
FinancingIn 2005, once Solexa became a US Nasdaq-listed company, it raised $97.5M in 8 months.
4The Cambridge Phenomenon Conference, Oct 5, 2010
5The Cambridge Phenomenon Conference, Oct 5, 2010
6The Cambridge Phenomenon Conference, Oct 5, 2010
...said Mr. West..."By sequencing a family of at least four we can ... interpret compound heterozygote variations in genes - those cases where multiple variations in a single gene, but on opposing chromosome copies, combine as a virtual homozygote. I expect that these are much more prevalent, and the source of much more phenotypic variability, than previously understood. Working with medical geneticists, we look forward to exploring this new visibility into factors influencing our future health."
7The Cambridge Phenomenon Conference, Oct 5, 2010
The Cambridge Phenomenon Conference, Oct 5, 2010
8
3.5 M SNPs (350k novel)
9,707 non-synonymoous SNPs per HPGP
2,428 trait-associated loci per HPGP report (1,716 unique)
GET-Evidence
(28)
OMIM (99)
HuGENet GWAS (1,133)
SNPedia (326)
HGMD (282)
Pharm GKB (28)
Other Hypotheses
(532)
Genome Analysis Summary to Date
John West
9/30/2010
2 loci in same drug metabolism gene re Nexium:Slow metaboliser
Ultra Fast MetabolizerAlso compound heterozygocity
Factor 5 Leiden &
Compound heterozygocity
Associated trait description includes
“diabetes” (95)
Type 1 (48)
Type 2 (45)
Diabetes non-specific (2)
.....
9The Cambridge Phenomenon Conference, Oct 5, 2010
10The Cambridge Phenomenon Conference, Oct 5, 2010
Market Scale Anecdotes
11The Cambridge Phenomenon Conference, Oct 5, 2010
Projected Adoption of Genome-Scale DNA sequencing
• Approx. 30 – 50 named individuals sequenced so far• A few research-clinical cases have saved lives, esp in cancer• Current capacity based on installed base of Illumina instruments
is 25 – 50,000 complete human genomes per year• Source of the gap:
– Research human genome sequencing is much larger– Many other research uses of DNA sequencing capacity– Price still falling: $2,000 by late 2011 ?
• Medical interpretation improving & action-ability transitioning:– Statistical association (probabilities of future disease)– Mechanism of action– Intervention to prevent or better treat
• Potential for ethical issues declines as this transition is made
12The Cambridge Phenomenon Conference, Oct 5, 2010
Stem Cell-Derived Therapy for Diabetes
13The Cambridge Phenomenon Conference, Oct 5, 2010
Financing Development of Stem Cell Derived Therapies
• Technology risk declining, but regulatory timing risk remains a challenge for investors & pharma
– Geron on clinical hold for almost 2 years– US Federal Government policy adds to perception of risk
• California Institute of Regenerative Medicine (CIRM) as a model for funding (aka Proposition 71):
– ViaCyte awarded $26M – of the scale needed for a major development– Additional $25M possible for clinical trials– Most CIRM funding has gone to universities
• Cost of initial developments are only affordable for major medical reimbursement categories, or for springboards to them
14The Cambridge Phenomenon Conference, Oct 5, 2010
Thank-you for your attention
John WestViaCyte, Inc
jwest@viacyte.com
+1 858 455 3677
15The Cambridge Phenomenon Conference, Oct 5, 2010